Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Matthew Galsky, MD, professor of medicine, director of Genitourinary Medical Oncology, director of the Novel Therapeutics Unit, co-director of the Center of Excellence for Bladder Cancer, Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Currently, based on data from several randomized phase 3 studies, platinum-based chemotherapy continues to be standard of care in treatment-naïve patients with metastatic urothelial cancer, according to Galsky.

However, if a patient has stable disease on imaging after at least 4 cycles of treatment, switch maintenance treatment with immune checkpoint blockade can be utilized, Galsky adds. This is supported by level 1 evidence from phase 3 studies that demonstrated a survival benefit with this approach, Galsky concludes.